ReviewCNS neuroscience & therapeutics2011
Pharmacological therapy in Parkinson's disease: focus on neuroprotection.
Review in CNS neuroscience & therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- UsingInternational journal of molecular sciences · 2025Pooled it
- Prediction of Metabolic Gene Biomarkers for Neurodegenerative Disease by an Integrated Network-Based Approach.BioMed research international · 2015Pooled it
- Mechanistic Insights, Treatment Paradigms, and Clinical Progress in Neurological Disorders: Current and Future Prospects.International journal of molecular sciences · 2023Review
- Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid.International journal of molecular sciences · 2021Review
- Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism.British journal of pharmacology · 2015Article
- Astrocytic JWA expression is essential to dopaminergic neuron survival in the pathogenesis of Parkinson's disease.CNS neuroscience & therapeutics · 2014Article
- Study of the neuroprotective effects of memantine in patients with mild to moderate ischemic stroke.Iranian journal of pharmaceutical research : IJPR · 2014Article
- Oxidative stress is not involved in motion sickness in mice.CNS neuroscience & therapeutics · 2013Article
- Kynurenines in Parkinson's disease: therapeutic perspectives.Journal of neural transmission (Vienna, Austria : 1996) · 2012Review
- Neuroprotection for stroke: current status and future perspectives.International journal of molecular sciences · 2012Review
- Adjunctive therapy in Parkinson's disease: the role of rasagiline.Neuropsychiatric disease and treatment · 2012Article
- Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.Journal of cellular and molecular medicine · 2011Review
- Neuroprotection in Parkinson's disease: a realistic goal?CNS neuroscience & therapeutics · 2010Article
- Kynurenines, neurodegeneration and Alzheimer's disease.Journal of cellular and molecular medicine · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the number of available therapeutic approaches in Parkinson's disease (PD) is steadily increasing the search for effective neuroprotective agent is continuing. Such research is directed at influencing the key steps in the pathomechanism: the mitochondrial dysfunction, the oxidative stress, the neuroinflammatory processes and the final common apoptotic pathway. Earlier-developed symptomatic therapies were implicated to be neuroprotective, and promising novel disease modifying approaches were brought into the focus of interest. The current review presents a survey of our current knowledge relating to the pathomechanism of PD and discusses the putative neuroprotective therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.